GlobeNewswire: Portola Pharmaceuticals, Inc. Contains the last 10 of 217 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:59:27ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/05/28/1853721/0/en/Portola-Pharmaceuticals-to-Participate-in-Two-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences2019-05-28T20:30:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will present a corporate overview at the following investor conferences in June:]]>https://www.globenewswire.com/news-release/2019/05/22/1840934/0/en/Portola-Pharmaceuticals-Announces-New-Analysis-from-the-ANNEXA-4-Study-of-its-Factor-Xa-Inhibitor-Reversal-Agent-Andexxa-in-Patients-with-Spontaneous-Non-Traumatic-Intracranial-Hem.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage2019-05-22T14:45:00Z<![CDATA[– Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage –]]>https://www.globenewswire.com/news-release/2019/05/08/1819333/0/en/Portola-Pharmaceuticals-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update2019-05-08T12:01:00Z<![CDATA[– First Quarter Revenues of $22.2 Million; Andexxa® Product Revenues Grow 45% to $20.3 Million –]]>https://www.globenewswire.com/news-release/2019/04/26/1810785/0/en/European-Commission-Grants-Conditional-Marketing-Authorization-for-Portola-Pharmaceuticals-Ondexxya-andexanet-alfa-the-First-and-Only-Antidote-for-the-Reversal-of-Factor-Xa-Inhibit.html?f=22&fvtc=4&fvtv=20016European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors2019-04-26T18:00:47Z<![CDATA[– Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalizedwith Life-Threatening Bleeding –]]>https://www.globenewswire.com/news-release/2019/04/24/1808762/0/en/Portola-Pharmaceuticals-Announces-Retirement-of-Dr-John-Curnutte-Executive-Vice-President-and-Head-of-Research-and-Development.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development2019-04-24T12:30:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Dr. John Curnutte, M.D., Ph.D., Executive Vice President and Head of Research and Development, will retire on May 17, 2019, after more than eight years of distinguished service. Dr. Curnutte will remain in a consultancy role, providing guidance to Portola’s President and Chief Executive Officer Scott Garland and engaging with key academic and scientific thoughtleaders in the field on the ongoing development of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] and cerdulatinib.]]>https://www.globenewswire.com/news-release/2019/04/17/1806096/0/en/Portola-Pharmaceuticals-to-Announce-First-Quarter-2019-Financial-Results-on-Wednesday-May-8-2019.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 20192019-04-17T20:15:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2019, and provide a general business overview on Wednesday, May 8, 2019, at 8:30 a.m. ET (5:30 a.m. PT).]]>https://www.globenewswire.com/news-release/2019/03/20/1758168/0/en/Portola-Pharmaceuticals-Co-Founder-Dr-Charles-Homcy-Retires-from-the-Company-s-Board-of-Directors.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors2019-03-20T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his decision to retire from the Board of Directors. Dr. Homcy co-founded the Company in 2003 and served as president and chief executive officer until April 2010, when he transitioned into his role on the Board of Directors, and became Chair of the Board’s Research and Development Committee. Dr. Homcy will remain in a consultancy role to Portola’s president and chief executive officer, Scott Garland, during the transition period. Dr. Homcy’s resignation from the Board will be effective upon execution of a consulting agreement. The Board is engaging in a search for a new independent Director to build upon the foundation that Dr. Homcy built when he co-founded Portola.]]>https://www.globenewswire.com/news-release/2019/03/06/1749178/0/en/Portola-Pharmaceuticals-to-Webcast-Presentation-at-Cowen-and-Company-s-39th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference2019-03-06T21:10:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will present a corporate overview at Cowen and Company’s 39th Annual Health Care Conference in Boston on Tuesday, March 12, 2019 at 8:40 a.m. ET (5:40 a.m. PT).]]>https://www.globenewswire.com/news-release/2019/03/01/1745256/0/en/Portola-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update2019-03-01T13:05:00Z<![CDATA[– Fourth Quarter Andexxa® Revenues of $14.0 Million; Third Consecutive Quarter of Strong Revenues –]]>https://www.globenewswire.com/news-release/2019/03/01/1745255/0/en/Portola-Pharmaceuticals-Enters-into-125-Million-Loan-Agreement-with-HealthCare-Royalty-Partners-and-Athyrium-Capital-Management.html?f=22&fvtc=4&fvtv=20016Portola Pharmaceuticals Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management2019-03-01T13:03:00Z<![CDATA[Agreement Provides Financial Flexibility for the Ongoing Commercialization of Andexxa® and Launch Preparations in Europe Agreement Provides Financial Flexibility for the Ongoing Commercialization of Andexxa® and Launch Preparations in Europe]]>